|1.||Kemp-Harper, Barbara K: 3 articles (09/2013 - 10/2011)|
|2.||Irvine, Jennifer C: 2 articles (09/2013 - 08/2013)|
|3.||Cheng, Robert Y S: 1 article (12/2014)|
|4.||Switzer, Christopher H: 1 article (12/2014)|
|5.||Basudhar, Debashree: 1 article (12/2014)|
|6.||Wink, David A: 1 article (12/2014)|
|7.||Ambs, Stefan: 1 article (12/2014)|
|8.||Heinecke, Julie L: 1 article (12/2014)|
|9.||Ridnour, Lisa A: 1 article (12/2014)|
|10.||Glynn, Sharon: 1 article (12/2014)|
05/01/2010 - "Since HNO is being investigated as a treatment for congestive heart failure, our results raise some concerns about the use of IPA/NO in the vasculature and suggest that further studies be conducted on the safety of HNO donors in the cardiovascular system."
11/26/2012 - "All these data suggest that O(2)-sulfonylethyl protected derivatives of IPA/NO, which are efficient HNO donors, could have potential applications to treat cardiovascular disease(s) such as congestive heart failure."
05/01/2010 - "The aims of this study are to determine the effect of IPA/NO on endothelial and vascular smooth muscle cells (VSMC) in vitro and to determine if IPA/NO inhibits neointimal hyperplasia in vivo. "
05/01/2010 - "In summary, while IPA/NO modestly inhibited neointimal hyperplasia by inhibiting VSMC proliferation and macrophage infiltration, it also inhibited endothelial cell proliferation and induced significant mortality in our animal model. "
05/01/2010 - "Isopropylamine NONOate (IPA/NO) moderates neointimal hyperplasia following vascular injury."
05/01/2010 - "Isopropylamine NONOate (IPA/NO) is a nitroxyl (HNO) donor at physiologic pH. HNO is a positive inotrope and vasodilator, but little is known about its effect on neointimal hyperplasia. "
|4.||Vascular System Injuries
|5.||Carotid Artery Injuries
|4.||Nitroprusside (Sodium Nitroprusside)
|6.||Aspirin (Acetylsalicylic Acid)